NoteHC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate Visibility agreement. See disclaimer.

Log in to your Inderes Free account to see all free content on this page.

BioPorto

1.462

DKK

-2.79 %

Less than 1K followers

BIOPOR

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

-2.79%

0%

-5.68%

-11.39%

-25.64%

-4.82%

-19.14%

-34.37%

-38.63%

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.

Market cap

628.18M DKK

Turnover

1.12M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Coverage

Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 10.12.2024

Financial calendar

20.3.

2025

Annual report '24

11.4.

2025

General meeting '25

8.5.

2025

Interim report Q1'25

ShowingAll content types

Regulatory press release6 hours ago

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

Regulatory press release2/27/2025, 5:05 PM

Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations

Regulatory press release1/29/2025, 5:16 PM

BioPorto A/S appoints new interim Chairman of the Board

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Bioporto: Preliminary 2024 figures

Analyst Comment1/7/2025, 7:20 AM by

Claus Thestrup, Philip Coombes

Bioporto: Preliminary 2024 figures

Bioporto: Preliminary 2024 figures

Regulatory press release1/6/2025, 5:16 PM

Preliminary Financial Figures for the 2024 Fiscal Year

Regulatory press release12/16/2024, 5:53 PM

BioPorto commences process to appoint new Chair of the Board of Directors

Bioporto (One-pager): Emerging as a Diagnostic growth company

Research12/10/2024, 10:47 AM by

Philip Coombes, Claus Thestrup

Bioporto (One-pager): Emerging as a Diagnostic growth company

The investment case for BioPorto focuses on leveraging the FDA marketing authorization of ProNephro AKI (NGAL) for pediatric use as a foundation for future approvals for adult use and broader applications

Regulatory press release11/14/2024, 7:50 AM

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

Regulatory press release11/4/2024, 5:44 PM

Grant of Warrants

Regulatory press release10/29/2024, 7:56 AM

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

Bioporto: Indgår partnerskab med Beckman Coulter om NGAL Tests til akut nyreskade

Analyst Comment10/29/2024, 7:36 AM by

Bioporto: Indgår partnerskab med Beckman Coulter om NGAL Tests til akut nyreskade

Selskabet annoncerer ny partnerskabsaftale med Beckman Coulter.

Regulatory press release10/28/2024, 3:26 PM

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

Bioporto: Wrap up from yesterday's event

Analyst Comment10/23/2024, 5:27 AM by

Bioporto: Wrap up from yesterday's event

Building the Global Commercial Platform for NGAL

BioPorto - Building the Global Commercial Platform

Webcast10/22/2024, 12:00 PM by

BioPorto - Building the Global Commercial Platform

Mest and ask questions to Jennifer Zonderman, Senior Vice President Global Marketing & US Commercialization, and hear her present the market characteristics and BioPorto's global commercial strategy within AKI diagnostics on 22 October at 2.00 PM.

Bioporto: AKI adult study - insights

Analyst Comment10/11/2024, 6:49 AM by

Claus Thestrup, Philip Coombes

Bioporto: AKI adult study - insights

The company revealed first insights to AKI adult study.

Dagens aktienyheder 15/08: TORM, Spar Nord, Skjern Bank, MapsPeople, ExpreS2ion Biotechnologies, Ascelia Pharma og BioPorto

Analyst Comment8/15/2024, 7:08 AM

Dagens aktienyheder 15/08: TORM, Spar Nord, Skjern Bank, MapsPeople, ExpreS2ion Biotechnologies, Ascelia Pharma og BioPorto

Dagens aktienyheder med TORM, Spar Nord, Skjern Bank, MapsPeople, ExpreS2ion Biotechnologies, Ascelia Pharma og BioPorto

Torm Spar Nord Bank Skjern Bank MapsPeople ExpreS2ion Biotech Holding Ascelia Pharma BioPorto

Regulatory press release8/15/2024, 6:37 AM

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024

BioPorto: Potential for labelling expansion of NGAL test

Analyst Comment8/8/2024, 9:16 AM by

Claus Thestrup, Henrik Ekman

BioPorto: Potential for labelling expansion of NGAL test

BioPorto's strategi includes labelling expansion

Regulatory press release7/4/2024, 3:54 PM

Grant of Warrants

Regulatory press release6/24/2024, 7:55 AM

Managers’ transactions

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.